ACURATE neo™ Aortic Valve System shows safety & efficacy results comparable to SAPIEN 3
Multi-centre propensity-matched comparison study1 between ACURATE neo Aortic Valve System and Edwards SAPIEN 3 Transcatheter Heart Valve, published in October’s edition of the Journal of the American College of Cardiology (JACC) shows comparable procedural outcomes.
Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial
Elderly patients regularly receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of double antiplatelet therapy (DAPT). The aim of this study was to compare outcomes between these two types of stents with a short duration of DAPT in such patients. Study concluded that BP-EES stent and a short duration of DAPT is better than BMS and a similar duration of DAPT with respect to the occurrence of all-cause mortality, myocardial infarction, stroke, and ischaemia-driven target lesion revascularisation.
SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve
Speaker: O. Wendler
Explore the SOURCE 3 Registry: Real-World Evidence With the Edwards SAPIEN 3 Transcatheter Heart Valve
At EuroPCR 2017, new one-year data from a post-approval study of the Edwards SAPIEN 3 valve demonstrated positive patient outcomes, including high survival rates, low rates of stroke, and low rates of paravalvular leak.
In this section, you will find content donated by our Industry Partners working in the field of Interventional Cardiovascular Disease. This content is considered to be of educational value and is not intended as advertising. Publication on this website does not equal endorsement. Discover the promoted content ...